Patients with recurrent vaginal candidiasis, defined as experiencing four or more documented episodes in one year with at least partial symptom resolution between episodes, should be considered for an induction-maintenance regime of oral fluconazole, according to NICE guidance. This involves prescribing an induction course of three doses of oral fluconazole 150 mg taken three days apart or an intravaginal antifungal for 10-14 days, followed by a maintenance regimen of six months of treatment with an oral or intravaginal antifungal.

While topical antifungals can be used for uncomplicated episodes of vaginal thrush, prescribing a course of topical treatment would be inappropriate for patients with recurrent symptoms. Instead, the induction-maintenance regime should be used.

Referral to gynaecology or dermatology may be appropriate for patients aged 12-15 years old, those with doubt about the diagnosis, those with unexplained treatment failure, or those with a non-albicans Candida species identified. Swabbing the discharge to confirm the diagnosis is important, but treatment should not be delayed for symptomatic patients. Therefore, starting treatment with the induction-maintenance protocol is appropriate for patients with recurrent infections.

Vaginal candidiasis, commonly known as ‘thrush’, is a prevalent condition that many women self-diagnose and treat. Candida albicans is responsible for 80% of cases, while other candida species cause the remaining 20%. Although most women have no predisposing factors, certain conditions such as diabetes mellitus, drug use (antibiotics, steroids), pregnancy, and immunosuppression (HIV) may increase the likelihood of developing vaginal candidiasis. Symptoms include non-offensive discharge resembling cottage cheese, vulvitis, dyspareunia, dysuria, itching, vulval erythema, fissuring, and satellite lesions.

Routine high vaginal swabs are not necessary if the clinical features are consistent with candidiasis. Treatment options include local or oral therapy. The NICE Clinical Knowledge Summaries recommends oral fluconazole 150 mg as a single dose as the first-line treatment. If oral therapy is contraindicated, a single dose of clotrimazole 500 mg intravaginal pessary may be used. If vulval symptoms are present, a topical imidazole may be added to an oral or intravaginal antifungal. Pregnant women should only use local treatments such as cream or pessaries, as oral treatments are not recommended.

Recurrent vaginal candidiasis is defined as four or more episodes per year by BASHH. Compliance with previous treatment should be checked, and the diagnosis of candidiasis should be confirmed. A high vaginal swab for microscopy and culture may be necessary, and a blood glucose test should be performed to exclude diabetes. Differential diagnoses such as lichen sclerosus should also be ruled out. An induction-maintenance regime may be used, consisting of oral fluconazole every three days for three doses as induction, followed by oral fluconazole weekly for six months as maintenance.

Special Situations for Combined Oral Contraceptive Pill

Concurrent Antibiotic Use:
In the UK, doctors have previously advised that taking antibiotics concurrently with the combined oral contraceptive pill may interfere with the enterohepatic circulation of oestrogen, making the pill ineffective. As a result, extra precautions were advised during antibiotic treatment and for seven days afterwards. However, this approach is not taken in the US or most of mainland Europe. In 2011, the Faculty of Sexual & Reproductive Healthcare updated their guidelines, abandoning the previous approach. The latest edition of the British National Formulary (BNF) has also been updated in line with this guidance. Precautions should still be taken with enzyme-inducing antibiotics such as rifampicin.

Switching Combined Oral Contraceptive Pills:
The BNF and Faculty of Sexual & Reproductive Healthcare (FSRH) appear to give contradictory advice on switching combined oral contraceptive pills. The Clinical Effectiveness Unit of the FSRH has stated in the Combined Oral Contraception guidelines that the pill-free interval doesn’t need to be omitted. However, the BNF advises missing the pill-free interval if the progesterone changes. Given the uncertainty, it is best to follow the BNF.

The FSRH advises that women who experience problematic bleeding for more than three months after starting the contraceptive implant should undergo a clinical examination, including a speculum, and be screened for sexually transmitted infections if they are at risk. If a woman is experiencing these symptoms, it is not recommended to repeat her smear test outside of the screening program. Instead, if her cervix appears abnormal, she should be referred for colposcopy.

Implanon and Nexplanon are both subdermal contraceptive implants that slowly release the hormone etonogestrel to prevent ovulation and thicken cervical mucous. Nexplanon is an updated version of Implanon with a redesigned applicator to prevent deep insertions and is radiopaque for easier location. It is highly effective with a failure rate of 0.07/100 women-years and lasts for 3 years. It doesn’t contain estrogen, making it suitable for women with a history of thromboembolism or migraines. It can be inserted immediately after a termination of pregnancy. However, a trained professional is needed for insertion and removal, and additional contraception is required for the first 7 days if not inserted on days 1-5 of the menstrual cycle.

The main disadvantage of these implants is irregular and heavy bleeding, which can be managed with a co-prescription of the combined oral contraceptive pill. Other adverse effects include headache, nausea, and breast pain. Enzyme-inducing drugs may reduce the efficacy of Nexplanon, and women should switch to a different method or use additional contraception until 28 days after stopping the treatment. Contraindications include ischaemic heart disease/stroke, unexplained vaginal bleeding, past breast cancer, severe liver cirrhosis, and liver cancer. Breast cancer is a UKMEC 4 condition, meaning it represents an unacceptable risk if the contraceptive method is used.

If the patient has missed two pills between days 8-14 of her cycle but has taken the previous 7 days of COCP correctly, emergency contraception is not necessary according to the Faculty of Sexual and Reproductive Health. Since the patient is not in need of emergency contraception, offering a hormonal-based option would be inappropriate. However, if emergency contraception is required, options include EllaOne (ulipristal acetate) up to 120 hours after unprotected intercourse or Levonelle (levonorgestrel) up to 96 hours after unprotected intercourse.

Inserting a copper IUD to prevent pregnancy would also be inappropriate in this case. If the patient is having difficulty remembering to take her pill correctly and is interested in long-acting contraception, counseling her on options such as intrauterine devices, subnormal contraceptive implants, and the contraceptive injection would be appropriate.

It is important to note that emergency contraception can be prescribed up to 120 hours after unprotected sexual intercourse, but its effectiveness decreases over time. Therefore, advising a patient to take emergency contraception within 12 hours would be incorrect.

The Faculty of Sexual and Reproductive Healthcare (FSRH) has updated their advice for women taking a combined oral contraceptive (COC) pill containing 30-35 micrograms of ethinylestradiol. If one pill is missed at any time during the cycle, the woman should take the last pill, even if it means taking two pills in one day, and then continue taking pills daily, one each day. No additional contraceptive protection is needed. However, if two or more pills are missed, the woman should take the last pill, leave any earlier missed pills, and then continue taking pills daily, one each day. She should use condoms or abstain from sex until she has taken pills for seven days in a row. If pills are missed in week one, emergency contraception should be considered if she had unprotected sex in the pill-free interval or in week one. If pills are missed in week two, after seven consecutive days of taking the COC, there is no need for emergency contraception. If pills are missed in week three, she should finish the pills in her current pack and start a new pack the next day, thus omitting the pill-free interval. Theoretically, women would be protected if they took the COC in a pattern of seven days on, seven days off.

According to NICE, women who are at a high risk of developing VTE and are seeking HRT should be referred to haematology before starting any treatment, even if it is transdermal.

While there is no evidence to suggest that transdermal HRT preparations such as patches or gels increase the risk of VTE, it is recommended to seek specialist advice before starting treatment if there are any risk factors present.

For patients with a high risk of VTE, oral HRT, whether it is combined or oestrogen-only, would be risky. Although per vaginal oestrogen would be a safer option, it would only provide local relief and may not alleviate all of the patient’s symptoms.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progestogen, to alleviate menopausal symptoms. However, this treatment can have side-effects such as nausea, breast tenderness, fluid retention, and weight gain.

Moreover, there are potential complications associated with HRT. One of the most significant risks is an increased likelihood of breast cancer, particularly when a progestogen is added. The Women’s Health Initiative (WHI) study found that the relative risk of developing breast cancer was 1.26 after five years of HRT use. The risk of breast cancer is related to the duration of HRT use, and it begins to decline when the treatment is stopped. Additionally, HRT use can increase the risk of endometrial cancer, which can be reduced but not eliminated by adding a progestogen.

Another potential complication of HRT is an increased risk of venous thromboembolism (VTE), particularly when a progestogen is added. However, transdermal HRT doesn’t appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any HRT treatment, even transdermal. Finally, HRT use can increase the risk of stroke and ischaemic heart disease if taken more than ten years after menopause.

In conclusion, while HRT can be an effective treatment for menopausal symptoms, it is essential to be aware of the potential adverse effects and complications associated with this treatment. Women should discuss the risks and benefits of HRT with their healthcare provider before starting any treatment.

Lesbian and bisexual women are at risk of contracting HPV, the virus responsible for causing cervical cancer, through genital contact or oral sex. As a result, it is important for them to undergo regular cervical screening. However, the uptake of screening among lesbian women is significantly lower than that of the general female population, often due to misinformation provided by healthcare providers.

Understanding Cervical Cancer Screening in the UK

Cervical cancer screening is a well-established program in the UK that aims to detect Premalignant changes in the cervix. This program is estimated to prevent 1,000-4,000 deaths per year. However, it should be noted that cervical adenocarcinomas, which account for around 15% of cases, are frequently undetected by screening.

The screening program has evolved significantly in recent years. Initially, smears were examined for signs of dyskaryosis, which may indicate cervical intraepithelial neoplasia. However, the introduction of HPV testing allowed for further risk stratification. Patients with mild dyskaryosis who were HPV negative could be treated as having normal results. The NHS has now moved to an HPV first system, where a sample is tested for high-risk strains of human papillomavirus (hrHPV) first, and cytological examination is only performed if this is positive.

All women between the ages of 25-64 years are offered a smear test. Women aged 25-49 years are screened every three years, while those aged 50-64 years are screened every five years. Cervical screening cannot be offered to women over 64, unlike breast screening, where patients can self-refer once past screening age. In Scotland, screening is offered from 25-64 every five years.

In special situations, cervical screening in pregnancy is usually delayed until three months postpartum, unless there has been missed screening or previous abnormal smears. Women who have never been sexually active have a very low risk of developing cervical cancer and may wish to opt-out of screening.

While there is limited evidence to support it, the current advice given out by the NHS is that the best time to take a cervical smear is around mid-cycle. Understanding the cervical cancer screening program in the UK is crucial for women to take control of their health and prevent cervical cancer.

Management of Endometriosis-Related Pain and Pelvic Inflammatory Disease

When it comes to managing endometriosis-related pain, a trial of paracetamol or an NSAID (alone or in combination) is recommended as first-line treatment. If this proves ineffective, other forms of pain management, including neuropathic pain treatment, should be considered. Hormonal treatment, such as COCP and POP, is also a sensible first-line option for women with suspected or confirmed endometriosis.

For pelvic inflammatory disease (PID), metronidazole + ofloxacin is often used as first-line treatment. However, there is no indication of this from the patient’s history. Referral to gynaecology would not add much at this stage, as they would likely offer the same options. Additionally, the patient is not keen on any surgical intervention at this point, which would include laparoscopy.

It’s important to note that GnRH agonists are not routinely started in primary care. They are sometimes started by gynaecology as an adjunct to surgery for deep endometriosis. Overall, a tailored approach to management is necessary for both endometriosis-related pain and PID, taking into account the individual patient’s needs and preferences.

HPV Triage in NHS Cervical Cancer Screening Programme

HPV triage is a new addition to the NHS cervical cancer screening programme. It involves testing cytology samples of women with borderline changes or mild dyskaryosis for high-risk HPV types that are linked to cervical cancer development. The aim is to refer only those who need further investigation and treatment, as low-grade abnormalities often resolve on their own.

If a woman tests negative for high-risk HPV, she is simply returned to routine screening recall. However, if she tests positive, she is referred for colposcopy. HPV testing is also used as a ‘test of cure’ for women who have been treated for cervical intraepithelial neoplasia and have returned for follow-up cytology. Those who are HPV negative are returned to 3 yearly recall. This new approach ensures that women receive the appropriate level of care and reduces unnecessary referrals for colposcopy.

A woman under 30 years old who presents with an unexplained breast lump, with or without pain, may not meet the 2-week-wait referral criteria but can still be referred for further evaluation. The most likely diagnosis is a fibroadenoma, which is a common benign breast lump that often occurs in younger women. These lumps are typically firm, smooth, and highly mobile, and can be described as a breast mouse due to their tendency to move away from the examiner’s hand. While a referral to a breast clinic is necessary, routine referral is appropriate given the low likelihood of cancer. There is no need to arrange mammograms or ultrasounds as these will be done by the breast clinic. Reviewing the patient in one month is unnecessary as the lump has persisted for two months and is not cyclical. Urgent referral to a breast clinic is not necessary given the patient’s age and low likelihood of breast cancer. According to NICE CKS, a 2-week-wait referral is recommended for those over 30 years old with an unexplained breast lump, or over 50 years old with unilateral nipple changes. Consideration of a 2-week-wait referral is also recommended for those over 30 years old with an unexplained lump in the axilla or skin changes suggestive of breast cancer.

In 2015, NICE released guidelines for referring individuals suspected of having breast cancer. If a person is 30 years or older and has an unexplained breast lump with or without pain, they should be referred using a suspected cancer pathway referral for an appointment within two weeks. Similarly, if a person is 50 years or older and experiences discharge, retraction, or other concerning changes in one nipple only, they should also be referred using this pathway. If a person has skin changes that suggest breast cancer or is 30 years or older with an unexplained lump in the axilla, a suspected cancer pathway referral should be considered for an appointment within two weeks. For individuals under 30 years old with an unexplained breast lump with or without pain, a non-urgent referral should be considered.

The initial treatment for cyclical mastalgia is a supportive bra and basic pain relief.

Cyclical breast pain is a common condition that affects up to two-thirds of women, typically beginning two weeks before their menstrual cycle. Breast pain, in the absence of other breast cancer symptoms such as a lump or changes in the nipple or skin, is not linked to breast cancer. Referral to a breast specialist may be considered if the pain is severe enough to impact quality of life or sleep and doesn’t respond to first-line treatment after three months, but there is no need for referral in this case.

Antibiotics are not recommended for the treatment of cyclical breast pain, as there is no evidence to support their use.

According to current NICE CKS guidelines, the combined oral contraceptive pill or progesterone-only pill should not be used to treat cyclical breast pain, as there is limited evidence of their effectiveness compared to a placebo.

The first-line approach to managing cyclical breast pain involves advising patients to wear a supportive bra and take basic pain relief. This is based on expert consensus, which suggests that most cases of cyclical breast pain can be managed conservatively with a watchful-waiting approach, as long as malignancy has been ruled out as a cause.

Cyclical mastalgia is a common cause of breast pain in younger females. It varies in intensity according to the phase of the menstrual cycle and is not usually associated with point tenderness of the chest wall. The underlying cause is difficult to identify, but focal lesions such as cysts may be treated to provide symptomatic relief. Women should be advised to wear a supportive bra and conservative treatments such as standard oral and topical analgesia may be used. Flaxseed oil and evening primrose oil are sometimes used, but neither are recommended by NICE Clinical Knowledge Summaries. If the pain persists after 3 months and affects the quality of life or sleep, referral should be considered. Hormonal agents such as bromocriptine and danazol may be more effective, but many women discontinue these therapies due to adverse effects.

Suspected Cervical Cancer

This patient should be suspected to have cervical cancer until proven otherwise, due to inflammation of the cervix that has been shown to be non-infective and no documented smear history, which puts her at higher risk. Empirical treatment for Chlamydia or gonorrhoea would not usually be suggested in general practice unless the patient has symptoms and signs of PID. Referring to an STD clinic is incorrect, as urgent investigation for cancer is necessary. Referring routinely to gynaecology is an option, but it doesn’t fully take into account the urgency of ruling out cervical cancer. Arranging a smear test for a lady with suspected cervical cancer would be inappropriate, as smear tests do not diagnose cancer, they only assess the likelihood of cancer occurring in the future.

To ensure reliable contraception, it is recommended to take a two-month course of Cerazette (desogestrel) as Nexplanon may not be dependable.

Implanon and Nexplanon are both subdermal contraceptive implants that slowly release the hormone etonogestrel to prevent ovulation and thicken cervical mucous. Nexplanon is an updated version of Implanon with a redesigned applicator to prevent deep insertions and is radiopaque for easier location. It is highly effective with a failure rate of 0.07/100 women-years and lasts for 3 years. It doesn’t contain estrogen, making it suitable for women with a history of thromboembolism or migraines. It can be inserted immediately after a termination of pregnancy. However, a trained professional is needed for insertion and removal, and additional contraception is required for the first 7 days if not inserted on days 1-5 of the menstrual cycle.

The main disadvantage of these implants is irregular and heavy bleeding, which can be managed with a co-prescription of the combined oral contraceptive pill. Other adverse effects include headache, nausea, and breast pain. Enzyme-inducing drugs may reduce the efficacy of Nexplanon, and women should switch to a different method or use additional contraception until 28 days after stopping the treatment. Contraindications include ischaemic heart disease/stroke, unexplained vaginal bleeding, past breast cancer, severe liver cirrhosis, and liver cancer. Breast cancer is a UKMEC 4 condition, meaning it represents an unacceptable risk if the contraceptive method is used.

For individuals who test positive for high-risk human papillomavirus (hrHPV) but receive a negative cytology report during routine primary HPV screening, the recommended course of action is to repeat the HPV test after 12 months. If the HPV test is negative at this point, the individual can return to routine recall. However, if the individual remains hrHPV positive and cytology negative, another HPV test should be conducted after a further 12 months. If the individual is still hrHPV positive after 24 months, they should be referred to colposcopy. It is important to note that repeating the cervical smear in 3 months or waiting 3 years for a repeat smear would not be appropriate in this scenario. Additionally, routine referral to colposcopy is not necessary unless there is abnormal cytology.

Understanding Cervical Cancer Screening Results

The cervical cancer screening program has evolved significantly in recent years, with the introduction of HPV testing allowing for further risk stratification. The NHS now uses an HPV first system, where a sample is tested for high-risk strains of human papillomavirus (hrHPV) first, and cytological examination is only performed if this is positive.

If the hrHPV test is negative, individuals can return to normal recall, unless they fall under the test of cure pathway, untreated CIN1 pathway, or require follow-up for incompletely excised cervical glandular intraepithelial neoplasia (CGIN) / stratified mucin producing intraepithelial lesion (SMILE) or cervical cancer. If the hrHPV test is positive, samples are examined cytologically, and if the cytology is abnormal, individuals will require colposcopy.

If the cytology is normal but the hrHPV test is positive, the test is repeated at 12 months. If the repeat test is still hrHPV positive and cytology is normal, a further repeat test is done 12 months later. If the hrHPV test is negative at 24 months, individuals can return to normal recall, but if it is still positive, they will require colposcopy. If the sample is inadequate, it will need to be repeated within 3 months, and if two consecutive samples are inadequate, colposcopy will be required.

For individuals who have previously had CIN, they should be invited for a test of cure repeat cervical sample in the community 6 months after treatment. The most common treatment for cervical intraepithelial neoplasia is large loop excision of transformation zone (LLETZ), which may be done during the initial colposcopy visit or at a later date depending on the individual clinic. Cryotherapy is an alternative technique.

Suspected Inflammatory Breast Cancer

This patient’s medical history raises concerns for inflammatory breast cancer, a rare but easily missed subtype of breast cancer. Despite accounting for only 1-5% of cases, inflammatory breast cancer can be difficult to diagnose and is often initially misdiagnosed as mastitis. The patient’s unilateral nipple retraction, which she attributes to breastfeeding, is also a suspicious sign. Therefore, it is crucial to have a high level of suspicion and refer the patient to a breast clinic urgently.

In this scenario, advising the patient to stop breastfeeding, massage the nipple, or use a breast shield would not be appropriate. Referring routinely without considering the severity of the potential diagnosis would also not be appropriate. It is essential to prioritize the patient’s health and well-being by taking swift and appropriate action.

It is now recommended to use both levonorgestrel and ulipristal more than once in the same menstrual cycle. According to the current guidelines from the Faculty of Sexual and Reproductive Healthcare (FSRH), if a woman has already taken either medication once or more in a cycle, she can be offered it again after further unprotected sexual intercourse in the same cycle. However, if she has already taken one medication, the other should not be taken within a certain timeframe. It is important to note that the intrauterine copper device is the most effective form of contraception and should be offered to eligible patients. Advising that no emergency contraception is needed when a woman is at risk of pregnancy is incorrect.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, and should be taken as soon as possible after unprotected sexual intercourse (UPSI) for maximum efficacy. The single dose of levonorgestrel is 1.5mg, but should be doubled for those with a BMI over 26 or weight over 70kg. It is safe and well-tolerated, but may cause vomiting in around 1% of women. Ulipristal, on the other hand, is a selective progesterone receptor modulator that inhibits ovulation. It should be taken within 120 hours after intercourse, and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which may inhibit fertilization or implantation. It must be inserted within 5 days of UPSI, or up to 5 days after the likely ovulation date. Prophylactic antibiotics may be given if the patient is at high-risk of sexually transmitted infection. The IUD is 99% effective regardless of where it is used in the cycle, and may be left in-situ for long-term contraception.

Blood stained discharge from the nipple is most commonly associated with an intraductal papilloma, which is a benign tumor that develops within the milk ducts of the breast. Surgical excision is the recommended treatment for papillomas, with histology performed to rule out any signs of breast cancer.

Breast fat necrosis, on the other hand, is typically caused by trauma and presents as a firm lump in the breast tissue. It is not associated with nipple discharge and usually resolves on its own.

Fibroadenomas are another type of benign breast lump that are small, non-tender, and mobile. They do not cause nipple discharge and do not require treatment.

Mammary duct ectasia is a condition where the breast ducts become dilated, often leading to blockage. It is most common in menopausal women and can cause nipple discharge, although this is typically thick, non-bloody, and green in color. Surgery may be necessary in some cases.

While pituitary prolactinoma is a possible cause of nipple discharge, it typically presents as bilateral and non-bloodstained. Larger prolactinomas can also cause vision problems due to pressure on the optic chiasm.

Understanding Nipple Discharge: Causes and Assessment

Nipple discharge is a common concern among women, and it can be caused by various factors. Physiological discharge may occur during breastfeeding, while galactorrhea may be triggered by emotional events or certain medications. Hyperprolactinemia, pituitary tumors, mammary duct ectasia, and intraductal papilloma are other possible causes of nipple discharge.

To assess patients with nipple discharge, a breast examination should be conducted to determine the presence of a mass lesion. If a mass is detected, triple assessment is recommended to evaluate the condition. Reporting of investigations should follow a system that uses a prefix denoting the type of investigation, such as M for mammography, followed by a numerical code indicating the findings.

For non-malignant nipple discharge, endocrine disease should be excluded, and smoking cessation advice may be given for duct ectasia. In severe cases of duct ectasia, total duct excision may be necessary. Nipple cytology is generally unhelpful in diagnosing the cause of nipple discharge.

Understanding the causes and assessment of nipple discharge is crucial in providing appropriate management and treatment for patients. Proper evaluation and reporting of investigations can help in identifying any underlying conditions and determining the best course of action.

Elevated Ca125 and Normal Examination: What to Do Next?

This patient has an elevated Ca125 but a normal examination. Although the elevated result was detected during screening, she admits to experiencing bloating, which can be an early symptom of ovarian cancer. However, it’s important to note that Ca125 can be elevated for non-malignancy reasons, and if the ovarian cancer is not epithelial in origin, the Ca125 can be normal.

According to NICE guidelines, if a woman has symptoms that suggest ovarian cancer, serum CA125 should be measured in primary care. If the serum CA125 is 35 IU/ml or greater, an ultrasound scan of the abdomen and pelvis should be arranged. If the ultrasound suggests ovarian cancer, the woman should be referred urgently for further investigation.

If a woman has a normal serum CA125 (less than 35 IU/ml) or a CA125 of 35 IU/ml or greater but a normal ultrasound, she should be assessed carefully for other clinical causes of her symptoms and investigated if appropriate. If no other clinical cause is apparent, she should be advised to return to her GP if her symptoms become more frequent and/or persistent.

In women aged 50-59 who do not use HRT, the background incidence of VTE is 5 cases per 1,000. The use of oestrogen-only HRT increases the incidence by 2 cases per 1,000, while combined HRT increases it by 7 cases per 1,000. According to the BNF, tibolone doesn’t elevate the risk of VTE when compared to combined HRT.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progestogen, to alleviate menopausal symptoms. However, this treatment can have side-effects such as nausea, breast tenderness, fluid retention, and weight gain.

Moreover, there are potential complications associated with HRT. One of the most significant risks is an increased likelihood of breast cancer, particularly when a progestogen is added. The Women’s Health Initiative (WHI) study found that the relative risk of developing breast cancer was 1.26 after five years of HRT use. The risk of breast cancer is related to the duration of HRT use, and it begins to decline when the treatment is stopped. Additionally, HRT use can increase the risk of endometrial cancer, which can be reduced but not eliminated by adding a progestogen.

Another potential complication of HRT is an increased risk of venous thromboembolism (VTE), particularly when a progestogen is added. However, transdermal HRT doesn’t appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any HRT treatment, even transdermal. Finally, HRT use can increase the risk of stroke and ischaemic heart disease if taken more than ten years after menopause.

In conclusion, while HRT can be an effective treatment for menopausal symptoms, it is essential to be aware of the potential adverse effects and complications associated with this treatment. Women should discuss the risks and benefits of HRT with their healthcare provider before starting any treatment.

If you experience ovarian hyperstimulation syndrome, your chances of developing ovarian torsion are higher. This is because the ovary becomes enlarged, which increases the risk of torsion. If you experience sudden pelvic pain and vomiting on one side, it may be a sign of ovarian torsion.

While an ovarian cyst can cause pelvic pain, the sudden onset of pain suggests a cyst accident, such as rupture, haemorrhage, or torsion.

Pelvic inflammatory disease typically causes pelvic pain, fever, and abnormal vaginal bleeding.

Appendicitis usually causes pain in the right iliac fossa.

Understanding Ovarian Torsion

Ovarian torsion is a condition where the ovary twists on its supporting ligaments, leading to a compromised blood supply. This can result in partial or complete torsion of the ovary. When the fallopian tube is also affected, it is referred to as adnexal torsion. The condition is commonly associated with ovarian masses, pregnancy, and ovarian hyperstimulation syndrome. Women of reproductive age are also at risk of developing ovarian torsion.

The most common symptom of ovarian torsion is sudden, severe abdominal pain that is often colicky in nature. Other symptoms include vomiting, distress, and in some cases, fever. Adnexal tenderness may be detected during a vaginal examination. Ultrasound may reveal free fluid or a whirlpool sign. Laparoscopy is usually both diagnostic and therapeutic for ovarian torsion.

Understanding Gynaecomastia: Causes, Symptoms, and Treatment Options

Gynaecomastia is a common condition characterized by the benign enlargement of male breast tissue. It affects more than 30% of men and can occur at any age, with prevalence increasing with age. The condition presents as a firm or rubbery mass that extends concentrically from the nipples. While usually bilateral, it can also be unilateral.

Gynaecomastia can be classified as physiological or pathological. Physiological gynaecomastia is seen in newborns, adolescents during puberty, and elderly men with low testosterone levels. Pathological causes include lack of testosterone, increased estrogen levels, liver disease, and obesity. Drugs, such as finasteride and spironolactone, can also cause gynaecomastia in adults.

In this scenario, the patient is likely being treated with a gonadorelin analogue for prostate cancer, which can cause side effects similar to orchidectomy. While the patient is overweight, his body mass index doesn’t meet the definition of obesity.

It is important to note that male breast cancer accounts for only 1% of all breast cancer cases. While unilateral swelling may increase the likelihood of breast cancer, other factors such as rapid growth, a hard irregular swelling, or a size greater than 5cm should also be considered.

Overall, understanding the causes, symptoms, and treatment options for gynaecomastia can help individuals make informed decisions about their health and seek appropriate medical care.

For women, the appropriate location to take swabs for chlamydia and gonorrhoea is the vulvo-vaginal area, specifically the introitus.

Chlamydia is the most common sexually transmitted infection in the UK caused by Chlamydia trachomatis. It is often asymptomatic but can cause cervicitis and dysuria in women and urethral discharge and dysuria in men. Complications include epididymitis, pelvic inflammatory disease, and infertility. Testing is done through nuclear acid amplification tests (NAATs) on urine or swab samples. Screening is recommended for sexually active individuals aged 15-24 years. Doxycycline is the first-line treatment, but azithromycin may be used if contraindicated. Partners should be notified and treated.

Breakthrough Bleeding and the Combined Pill

Breakthrough bleeding is a common issue that can occur when taking the combined pill. It is important to first check compliance with pill usage, as missed pills or erratic usage can lead to bleeding problems. Other factors such as intercurrent illness or the use of other medications should also be considered. Pregnancy should be ruled out with a test, especially if any pills have been missed or pill efficacy has been compromised. Additionally, sexually transmitted infections should be considered and appropriate tests performed.

For women who have recently started using the combined pill, breakthrough bleeding is a common occurrence in the first few months of use. It is important to discuss this with a healthcare provider and be reassured that it usually settles with time. If breakthrough bleeding persists, a change in approach may be necessary. Lower dose pills (20 mcg ethinyloestradiol) are more likely to cause breakthrough bleeding, and switching to a higher dose pill (30 mcg) may be an option. Overall, it is important to address breakthrough bleeding promptly to ensure the effectiveness and safety of the combined pill.

Breast cancer treatment often involves hormonal therapy, particularly for those with estrogen receptor-positive tumors (which account for about 80% of all breast cancers). Aromatase inhibitors like anastrozole are commonly used in postmenopausal women to target estrogen production.

However, one of the major concerns with hormonal therapy is the risk of osteoporosis. Women should undergo bone mineral density testing before starting treatment and regularly thereafter.

Tamoxifen, another drug commonly used to treat breast cancer, has been associated with side effects such as deep vein thrombosis, endometrial cancer, and vaginal bleeding. However, urinary incontinence is not a known side effect of anastrozole.

Anti-oestrogen drugs are used in the management of oestrogen receptor-positive breast cancer. Selective oEstrogen Receptor Modulators (SERM) such as Tamoxifen act as an oestrogen receptor antagonist and partial agonist. However, Tamoxifen may cause adverse effects such as menstrual disturbance, hot flashes, venous thromboembolism, and endometrial cancer. On the other hand, aromatase inhibitors like Anastrozole and Letrozole reduce peripheral oestrogen synthesis, which is important in postmenopausal women. Anastrozole is used for ER +ve breast cancer in this group. However, aromatase inhibitors may cause adverse effects such as osteoporosis, hot flashes, arthralgia, myalgia, and insomnia. NICE recommends a DEXA scan when initiating a patient on aromatase inhibitors for breast cancer.

Investigation is necessary for any ovarian mass found in a woman who has undergone menopause.

When a patient presents with suspected ovarian cysts or tumors, the first imaging modality used is typically ultrasound. The ultrasound report will indicate whether the cyst is simple or complex. Simple cysts are unilocular and more likely to be benign, while complex cysts are multilocular and more likely to be malignant. Management of ovarian enlargement depends on the patient’s age and whether they are experiencing symptoms. It is important to note that ovarian cancer diagnosis is often delayed due to a vague presentation.

For premenopausal women, a conservative approach may be taken, especially if they are younger than 35 years old, as malignancy is less common. If the cyst is small (less than 5 cm) and reported as simple, it is highly likely to be benign. A repeat ultrasound should be scheduled for 8-12 weeks, and referral should be considered if the cyst persists.

Postmenopausal women, on the other hand, are unlikely to have physiological cysts. Any postmenopausal woman with an ovarian cyst, regardless of its nature or size, should be referred to gynecology for assessment.

For women over 40, it is recommended to consider a COC pill containing less than 30 µg ethinylestradiol as the first-line option due to the potentially lower risks of VTE, cardiovascular disease, and stroke compared to formulations with higher doses of estrogen. COCP can also help reduce menstrual bleeding and pain, which may be beneficial for women in this age group. However, it is important to consider special considerations when prescribing COCP to women over 40.

Levonorgestrel or norethisterone-containing COCP preparations should be considered as the first-line option for women over 40 due to the potentially lower risk of VTE compared to formulations containing other progestogens. The UKMEC criteria for women over 40 is 2, while for women from menarche until 40, it is 1. The faculty of sexual and reproductive health recommends the use of COCP until age 50 if there are no other contraindications. Women aged 50 and over should be advised to use an alternative, safer method for contraception.

Extended or continuous COCP regimens can be offered to women for contraception and to control menstrual or menopausal symptoms. COCP is associated with a reduced risk of ovarian and endometrial cancer that lasts for several decades after cessation. It may also help maintain bone mineral density compared to non-use of hormones in the perimenopause.

Although meta-analyses have found a slightly increased risk of breast cancer among women using COCP, there is no significant risk of breast cancer ten years after cessation. Women who smoke should be advised to stop COCP at 35 as this is the age at which excess risk of mortality associated with smoking becomes clinically significant.

Women over the age of 40 still require effective contraception until they reach menopause, despite a significant decline in fertility. The Faculty of Sexual and Reproductive Healthcare (FSRH) has produced specific guidance for this age group, titled Contraception for Women Aged Over 40 Years. No method of contraception is contraindicated by age alone, with all methods being UKMEC1 except for the combined oral contraceptive pill (UKMEC2 for women >= 40 years) and Depo-Provera (UKMEC2 for women > 45 years). The FSRH guidance provides specific considerations for each method, such as the use of COCP in the perimenopausal period to maintain bone mineral density and reduce menopausal symptoms. Depo-Provera use is associated with a small loss in bone mineral density, which is usually recovered after discontinuation. The FSRH also provides a table detailing how different methods may be stopped based on age and amenorrhea status. Hormone replacement therapy cannot be relied upon for contraception, and a separate method is needed. The FSRH advises that the POP may be used in conjunction with HRT as long as the HRT has a progestogen component, while the IUS is licensed to provide the progestogen component of HRT.

If a woman has symptoms of candidiasis or BV and is unlikely to have an STI or serious illness, vaginal examination may be unnecessary. However, if a woman has vaginal discharge and a history of BV or candidiasis, and is not pregnant or postnatal, and has not recently undergone a gynecological procedure, examination should not be omitted.

Understanding Vaginal Discharge: Common and Less Common Causes

Vaginal discharge is a common symptom experienced by many women, but it is not always a sign of a serious health issue. In fact, some amount of discharge is normal and helps to keep the vagina clean and healthy. However, when the discharge is accompanied by other symptoms such as itching, burning, or a foul odor, it may be a sign of an underlying condition.

The most common causes of vaginal discharge include Candida, Trichomonas vaginalis, and bacterial vaginosis. Candida is a fungal infection that can cause a thick, white discharge that resembles cottage cheese. Trichomonas vaginalis is a sexually transmitted infection that can cause a yellow or green, frothy discharge with a strong odor. Bacterial vaginosis is a bacterial infection that can cause a thin, gray or white discharge with a fishy odor.

Less common causes of vaginal discharge include gonorrhea, chlamydia, ectropion, foreign bodies, and cervical cancer.

Bartholin’s cysts that are asymptomatic do not need any treatment and can be managed conservatively.

In cases where the cysts are recurrent or causing discomfort, marsupialisation or balloon catheter insertion can be considered as management options. These procedures have been shown to decrease the likelihood of recurrence.

If an abscess is suspected, antibiotics may be necessary. Symptoms of an abscess include pain, swelling, redness, and fever.

Women who are 40 years old or older should be referred for a biopsy to rule out the possibility of carcinoma.

Bartholin’s cyst occurs when the Bartholin duct’s entrance becomes blocked, causing mucous to build up behind the blockage and form a mass. This blockage is usually caused by vulval oedema and is typically sterile. These cysts are often asymptomatic and painless, but if they become large, they may cause discomfort when sitting or superficial dyspareunia. On the other hand, Bartholin’s abscess is extremely painful and can cause erythema and deformity of the affected vulva. Bartholin’s abscess is more common than the cyst, likely due to the asymptomatic nature of the cyst in most cases.

Bartholin’s cysts are usually unilateral and 1-3 cm in diameter, and they should not be palpable in healthy individuals. Limited data suggest that around 3000 in 100,000 asymptomatic women have Bartholin’s cysts, and these cysts account for 2% of all gynaecological appointments. The risk factors for developing Bartholin’s cyst are not well understood, but it is thought to increase in incidence with age up to menopause before decreasing. Having one cyst is a risk factor for developing a second.

Asymptomatic cysts generally do not require intervention, but in older women, some gynaecologists may recommend incision and drainage with biopsy to exclude carcinoma. Symptomatic or disfiguring cysts can be treated with incision and drainage or marsupialisation, which involves creating a new orifice through which glandular secretions can drain. Marsupialisation is more effective at preventing recurrence but is a longer and more invasive procedure. Antibiotics are not necessary for Bartholin’s cyst without evidence of abscess.

References:
1. Berger MB, Betschart C, Khandwala N, et al. Incidental Bartholin gland cysts identified on pelvic magnetic resonance imaging. Obstet Gynecol. 2012 Oct;120(4):798-802.
2. Kaufman RH, Faro S, Brown D. Benign diseases of the vulva and vagina. 5th ed. Philadelphia, PA: Elsevier Mosby; 2005:240-249.
3. Azzan BB. Bartholin’s cyst and abscess: a review of treatment of 53 cases. Br J Clin Pract. 1978 Apr;32(4):101-2.

Clonidine is the only option listed above that is recognized as a non-hormonal treatment for hot flashes during menopause. Amitriptyline is an antidepressant, Tibolone is a synthetic compound with estrogenic, progestogenic, and androgenic activity, Danazol is a synthetic steroid that suppresses gonadotropin production, and Clomiphene is a selective estrogen receptor modulator used in fertility treatments. According to the NICE Clinical Knowledge Summaries article on treating menopause symptoms, non-hormonal therapies for hot flashes include lifestyle changes, a trial of certain medications such as paroxetine, fluoxetine, citalopram, or venlafaxine, a 24-week trial of clonidine, or a progestogen like norethisterone or megestrol (with specialist advice).

Managing Menopause: Lifestyle Modifications, HRT, and Non-HRT Options

Menopause is a natural biological process that marks the end of a woman’s reproductive years. It is diagnosed when a woman has not had a period for 12 months. Menopausal symptoms are common and can last for several years. The management of menopause can be divided into three categories: lifestyle modifications, hormone replacement therapy (HRT), and non-hormone replacement therapy.

Lifestyle modifications can help manage symptoms such as hot flashes, sleep disturbance, mood changes, and cognitive symptoms. Regular exercise, weight loss, stress reduction, and good sleep hygiene are recommended.

HRT is an effective treatment for menopausal symptoms, but it is not suitable for everyone. Women with current or past breast cancer, any oestrogen-sensitive cancer, undiagnosed vaginal bleeding, or untreated endometrial hyperplasia should not take HRT. HRT brings certain risks, including an increased risk of venous thromboembolism, stroke, coronary heart disease, breast cancer, and ovarian cancer.

Non-HRT options include fluoxetine, citalopram, or venlafaxine for vasomotor symptoms, vaginal lubricants or moisturisers for vaginal dryness, self-help groups, cognitive behaviour therapy, or antidepressants for psychological symptoms, and vaginal oestrogen for urogenital symptoms.

When stopping HRT, it is important to gradually reduce the dosage to limit recurrence in the short term. Women should be referred to secondary care if treatment has been ineffective, if there are ongoing side effects, or if there is unexplained bleeding.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progestogen, to alleviate menopausal symptoms. However, this treatment can have side-effects such as nausea, breast tenderness, fluid retention, and weight gain.

Moreover, there are potential complications associated with HRT. One of the most significant risks is an increased likelihood of breast cancer, particularly when a progestogen is added. The Women’s Health Initiative (WHI) study found that the relative risk of developing breast cancer was 1.26 after five years of HRT use. The risk of breast cancer is related to the duration of HRT use, and it begins to decline when the treatment is stopped. Additionally, HRT use can increase the risk of endometrial cancer, which can be reduced but not eliminated by adding a progestogen.

Another potential complication of HRT is an increased risk of venous thromboembolism (VTE), particularly when a progestogen is added. However, transdermal HRT doesn’t appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any HRT treatment, even transdermal. Finally, HRT use can increase the risk of stroke and ischaemic heart disease if taken more than ten years after menopause.

In conclusion, while HRT can be an effective treatment for menopausal symptoms, it is essential to be aware of the potential adverse effects and complications associated with this treatment. Women should discuss the risks and benefits of HRT with their healthcare provider before starting any treatment.

Topical Oestrogens for Genitourinary Symptoms of Menopause

Topical oestrogens can be used alongside transdermal/oral HRT to treat genitourinary symptoms of menopause. In fact, systemic HRT doesn’t improve these symptoms in 10-15% of women. Topical oestrogens are effective in these cases and can be combined with systemic HRT.

Combined HRT is not better than oestrogen-only therapy for treating genitourinary symptoms, and progestogens are only used for endometrial protection. If a patient already has protection via an IUS, combination therapy would not be beneficial. Topical oestrogen preparations have been shown to improve vaginal symptoms, including vaginal atrophy and pH decrease, and to increase epithelial maturation compared to placebo or non-hormonal gels.

It is important to note that systemic absorption of vaginal oestrogen is very low. Therefore, topical oestrogens work better for genitourinary symptoms of menopause compared to oral HRT and can be used in combination. According to NICE NG23, vaginal oestrogen should be offered to women with urogenital atrophy, including those on systemic HRT, and treatment should continue for as long as needed to relieve symptoms.

If vaginal oestrogen doesn’t relieve symptoms, the dose can be increased after seeking advice from a healthcare professional with expertise in menopause. Women should be informed that symptoms often return when treatment is stopped, but adverse effects from vaginal oestrogen are very rare. They should report any unscheduled vaginal bleeding to their GP. Additionally, moisturisers and lubricants can be used alone or in addition to vaginal oestrogen for vaginal dryness. Routine monitoring of endometrial thickness during treatment for urogenital atrophy is not necessary.